Currently available methods for treatment of human prostatic carcinoma aim to inactivate the androgen receptor (AR) by androgen deprivation or blockade with anti-androgens. Failure of endocrine therapy and tumor progression is characterized by androgenindependent growth despite high levels of AR expression in metastatic disease. We inhibited AR expression in LNCaP prostate tumor cells by using antisense AR oligodeoxynucleotides (ODNs) and explored whether antisense AR treatment would be conceivable as a therapy for advanced prostate cancer. Among the various AR antisense ODNs tested, a 15-base ODN targeting the CAG repeats encoding the poly-glutamine region of the AR (as750/15) was found to be most effective. Treatment of LNCaP cells with as750/15 reduced AR expression to ϳ2% within 24 hours compared with mock-treated controls. AR down-regulation resulted in significant cell growth inhibition, strongly reduced secretion of the androgen-regulated prostate-specific antigen, reduction of epidermal growth factor receptor expression, and an increase in apoptotic cells. Mis-sense and mismatched control ODNs had no or only slight effects. Antisense inhibition was also very efficient in LNCaP-abl cells, a subline established after long-term androgen ablation of LNCaP cells, resulting in inhibition of AR expression and cell proliferation that was similar to that seen for parental LNCaP cells. This study shows that inhibition of AR expression by antisense AR ODNs may be a promising new approach for treatment of advanced human prostate cancer. Cancer Gene Therapy (2000) 7, 997-1007
N on-organ confined prostatic carcinoma is treated by surgical or pharmacological castration. The aim of therapy is to prevent androgenic stimulation of the tumor. Androgen ablation is often combined with blockade of the androgen receptor (AR) by various antiandrogens. 1 As androgens regulate growth and development of the prostate gland, 2 androgen deprivation results in induction of programmed cell death. 3 However, most tumors, initially sensitive to such kind of hormonal therapy, progress and become androgen-independent. Therefore, beneficial effects are only palliative and non-organ confined prostatic carcinoma is not curable.
Recent findings led us to the assumption that the AR plays a critical role in hormonal therapy-resistant prostate cancer and led us to inhibit AR expression by antisense oligodeoxynucleotides (ODNs). The most important finding was the proof that the AR is expressed not only in primary prostate tumors 4, 5 but also in their corresponding metastatic lesions, as shown in vivo in immunohistochemical studies. 6, 7 It has become clear that progression from androgen-dependent to androgen-independent prostate tumor growth is not associated with loss of the AR. This knowledge is in contrast to findings that the two human metastatic prostate cancer cell lines PC-3 and DU-145 and advanced rat Dunning tumors do not express the AR. 8 -10 Immunohistochemical results were further supported by the detection of AR gene amplification that occurs in about one-third of tumors in conjunction with the development of therapy resistance. 11 In addition, these studies showed increased AR mRNA levels in tumors with AR gene amplification and even in some tumors with a single AR gene. 12 When long-term androgen ablation therapy is simulated in the LNCaP tumor model, these cells also up-regulate the AR at the mRNA and protein level and become hypersensitive to small concentrations of androgens. 13, 14 Another important fact is the occurrence of AR gene mutations that can result in a promiscuous receptor with a broad hormone binding and transactivation spectrum. 15, 16 Activation of mutated AR has been shown for steroid hormones such as estrogens, progestins, adrenal androgens, and dihydrotestosterone metabolites, and even for the nonsteroidal anti-androgens flutamide and nilutamide. [17] [18] [19] [20] [21] Prostate tumor progression can also be accompanied by AR activation through growth factors and protein kinase A activators. Ligand-independent activation of the AR by various growth factors, such as insulin-like growth factor-I (IGF-I), keratinocyte growth factor, epidermal growth factor (EGF), cyclic adenosine monophosphate analogs, and forskolin, and by luteinizing hormone-releasing hormone has been described previously. [22] [23] [24] We reasoned that if AR expression could be prevented or at least reduced, this should be the most efficient blockade of the androgen-signaling cascade and therefore should be a promising new approach for therapy of hormone-resistant prostatic carcinoma. Herein, we describe for the first time the use of AR antisense ODNs to inhibit AR expression in LNCaP and LNCaP-abl prostate tumor cells. LNCaP cells, derived from a lymph node from a patient with carcinoma of the prostate, express AR and secrete prostate-specific antigen (PSA). 25, 26 The subline LNCaP-abl was established by long-time growth of LNCaP cells in steroid-deprived medium.
14 These cells display increased AR protein levels associated with androgen hypersensitivity and growth in castrated mice.
We tested ODNs targeting either the translation start site or the two triplet repeats within the mRNA region encoding the AR N-terminus. 27, 28 The latter antisense oligonucleotides proved to be highly effective in suppression of AR expression and inhibition of the growth of LNCaP and LNCaP-abl cells.
MATERIALS AND METHODS

Cell culture
LNCaP cells were obtained from the American Type Culture Collection (Manassas, Va). Cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 in RPMI 1640 (Hyclone, Logan, Utah) supplemented with penicillin/streptomycin (100 international units/mL and 100 g/mL, respectively) and 10% fetal calf serum (FCS) (PAA Laboratories, Linz, Austria). Passaging was routinely performed with trypsin/ethylenediaminetetraacetic acid (EDTA) (0.05% and 0.02%, respectively; PAA Laboratories).
LNCaP-abl cells were recently established in our laboratory by long-term culture of LNCaP cells in steroid-deprived medium. 14 The AR protein level is increased ϳ3-fold in these cells. They respond in a hypersensitive manner to androgen stimulation and, in contrast to parental LNCaP cells, grow in castrated mice. LNCaP-abl cells were grown in RPMI 1640 supplemented with penicillin/streptomycin and 10% charcoalstripped FCS and routinely passaged with trypsin/EDTA.
Electroporation of oligonucleotides
Antisense phosphorothioate-ODNs were purchased from Eurogentec (Brussels, Belgium). Sequences of ODNs are summarized in Table 1 . Mis-sense control ODNs had a random sequence, whereas mismatched control ODNs had the sequence of the antisense ODN with four bases replaced to eliminate antisense effects. All ODNs consisted of 15 bases with thioate modifications at each nucleotide. LNCaP cells in log phase were trypsinized, and 9 ϫ 10 5 cells were suspended in 400 L Hank's balanced salt solution (Boehringer Ingelheim, Heidelberg) supplemented with 1 mM spermidine (Sigma, St. Louis, Mo). ODNs were added to a final concentration of 7.5 M. Cell suspensions were placed into a 0.4-cm electroporation chamber and electroporated using an Easyject Cell Porator Electroporation System (Eurogentec). Optimal electroporation parameters were worked out to yield a high cell viability and transfection efficiency in LNCaP cells: a low-voltage pulse (220 V, 1050 F, 201 ⍀) immediately followed a high-voltage pulse (650 V, 25 F, 99 ⍀). After electroporation, cells were quickly transferred into RPMI 1640 containing 10% FCS, centrifuged (1000 rpm, 3 minutes) to eliminate remaining ODNs, and seeded into 6-well plates in culture medium. In control experiments, efficient uptake of ODNs was demonstrated by means of fluorescence-activated cell sorter analysis and a fluorescence-labeled control ODN (data not shown).
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was isolated from cells using a Total RNA Isolation System (Promega, Madison, Wis). After denaturation (94°C, 2 minutes), 500 ng of RNA was transcribed into cDNA using a Ready-To-Go kit (You-Prime-First-Strand-Beads; Pharmacia, Uppsala, Sweden). cDNA fragments of AR and 
Immunoblotting
Cell pellets were suspended in lysis buffer (20 mM NaH 2 PO 4 (pH 7.5), 1 mM EDTA, 10% glycerol, and 0.1% monothioglycerol) and lysed by ultrasound for 5 minutes and by three subsequent cycles of freezing in liquid nitrogen and thawing on ice water. Total amounts of protein were determined by the method of Bradford. 29 A total of 20 g of total protein were then mixed with 5ϫ sample buffer (2.5 mL of 1.25 M Tris (pH 6.8), 5 mL of glycerin, 2.5 mL of 2-mercaptoethanol, 4 mg of bromophenol blue, and 1 g of sodium dodecyl sulfate), denatured at 90°C for 2 minutes, and separated on an 8% polyacrylamide gel. Proteins were transferred onto an Immobilon-P membrane (Millipore, Bedford, Mass). Blots were incubated sequentially with 1% nonfat dry milk at room temperature for at least 1 hour, diluted 1/500 with mouse monoclonal anti-AR antibody (Genentec, San Francisco, Calif) at 4°C overnight, diluted 1/2200 with secondary horseradish peroxidase-conjugated anti mouse immunoglobulin G (Santa Cruz Biotechnology, Santa Cruz, Calif) for 1 hour at room temperature, and evaluated using the enhanced chemiluminescence system from Amersham (Little Chalfont, UK). AR protein band intensities were determined densitometrically using a video imaging system and IPLab Gel 2.0 program.
Cell proliferation assay
Cells were electroporated with or without ODNs and seeded into 24-well plates (Sarstedt, Newton, NC). Cell mass was determined by a colorimetric EZ4U 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay (Biomedica, Vienna, Austria) according to the manufacturer's instructions. Briefly, cells were washed once with phosphate-buffered saline (PBS) (PAA Laboratories) and subsequently incubated for 2 hours at 37°C in a substrate solution containing 60 L of substrate in 600 L of PBS per well. Units of absorption (UA) were measured on a photometer at 550 nm.
Quantitation of PSA in cell culture supernatants
Amounts of PSA were determined in cell culture supernatants using a microparticle enzyme immunoassay (MEIA) kit (Abbott Laboratories, Abbott Park, Ill). PSA levels were related to cell mass as determined by MTT assay and were expressed as nanograms of PSA per UA.
Apoptosis
Nonelectroporated control cells were seeded on 6-well-plates (Falcon Primaria; Becton Dickinson, Franklin Lakes, NJ) at a density of 1.5 ϫ 10 5 cells/well in normal growth medium (10% FCS, RPMI 1640). Electroporation with or without ODNs was performed as described above and cells were seeded onto 6-well plates immediately afterward. After 24 hours, medium was replaced by serum-reduced RPMI 1640 (1% FCS). At this time, mibolerone was added to a final concentration of 5 nM. The percentage of apoptotic cells was determined after an additional 24 hours using an annexin V detection kit (Genzyme, Cambridge, Mass). Briefly, cells were trypsinized, washed twice with PBS, and stained with annexin V/propidium iodide for 15 minutes at room temperature. Annexin V binding was assessed by flow cytometry (FACScalibur; Becton Dickinson) within 1 hour.
EGF receptor (EGFR) enzyme-linked immunosorbent assay (ELISA)
Cells were scraped off, washed once with PBS, and resuspended in PBS. The total cell number was determined with a Coulter counter (Coulter, Hialeah, Fla). After centrifugation (1800 rpm, 5 minutes), pellets were suspended in 100 L of TE buffer (50 mM Tris, 5 mM EDTA (pH 7.4)) and lysed with 20 L of antigen extraction agent for 30 minutes on ice. Another centrifugation step was performed to remove cell debris (10,000 rpm, 5 minutes). Supernatants were frozen at Ϫ80°C until measurement. For quantitation of EGFR, samples were diluted 1/6 in sample diluent. We used a commercial ELISA kit (Oncogene Research Products, Cambridge, Mass) according to the manufacturer's instructions. Amounts of EGFR (fmol/ mL) were corrected for cell number and indicated as femtomoles of EGFR per 10 5 cells.
Statistical analysis
Results were expressed as means Ϯ SD. P values of Ͻ0.05 were considered statistically significant. Statistical significance between groups was assessed by the Mann-Whitney U test (unpaired t test, two-sided).
RESULTS
Antisense-mediated inhibition of AR expression in LNCaP cells
We tested the efficacy of several phosphorothioate antisense ODNs targeting various regions of the human AR in diminishing AR expression. ODNs directed against the translation start region of the AR mRNA comprising nucleotides 529 -548 and 549 -568, (nucleotide numbers according to Ref. 30) revealed only a slight downregulation of the AR protein level and nonspecific side effects of random control ODNs (data not shown). Therefore, we tested ODNs that are directed to the CAG and the GGC repeats encoding the N-terminal poly-glutamine (as750/15) and the poly-glycine (as1944/ 15) regions of the human AR, respectively. ODNs were delivered by electroporation, as simple incubation of cells with ODNs alone did not change AR expression levels (data not shown). As demonstrated in Figure 1 , electroporation of LNCaP cells with 7.5 M of either as750/15 ( Fig 1A) or as1944/15 ( Fig 1B) resulted in a marked reduction of AR mRNA levels within 6 -24 hours after electroporation. Similarly, AR protein levels were reduced by as750/15 as well as by as1944/15 ODNs, as determined by immunoblot analysis (Fig 2) . AR protein levels were downregulated to Ͻ2% within 24 hours after treatment with as750/15 (Fig 2A) or as1944/15 ( Fig 2B) compared with mock-treated controls. Down-regulation of AR protein persisted for at least 72 hours, although maximal effects were observed 24 hours after electroporation (Fig 2, A  and B) .
To ensure specificity of antisense AR ODNs, we have chosen random control ODNs (ms1944/15, ms750/15) as well as a mismatched control analog (mm750/15). No effects on AR expression were observed on mRNA (Fig  1) or on protein levels (Fig 2) when cells were electroporated in the presence of 7.5 M control ODNs. This result further shows that the exchange of four nucleotides eliminates the antisense effect of the as750/15 ODN.
Growth inhibition of LNCaP cells treated with AR antisense ODNs
To determine whether AR down-regulation resulted in an inhibition of prostate tumor cell growth, cell mass was evaluated at 8, 24, 48, and 72 hours after electroporation in the absence or presence of ODNs using a MTT cell viability assay (Fig 3) . Treatment with either as750/15 or as1944/15 yielded a significant inhibition of LNCaP cell growth by 73% and 61%, respectively, within 72 hours after electroporation (P Ͻ .01) compared with mocktreated controls. The control ODNs ms750/15 and mm750/15, respectively, did not affect cell growth. The control ODN ms1944/15 had a small but insignificant effect. The antiproliferative effect of the antisense ODN as750/15 was evident already 24 hours after treatment, whereas the as1944/15 ODN elicited its effect 48 hours after electroporation. After these timepoints, there was a complete arrest of growth in the antisense ODNtreated cells. Mock-treated cells that were incubated with 1 M of the nonsteroidal anti-androgen bicalutamide (Casodex) for 72 hours showed only ϳ24% growth retardation.
To further investigate AR specificity, we tested the ODNs in DU-145 cells. These prostate cancer cells, which are derived from a brain metastasis, do not express the AR and grow independent of androgen. As shown in Figure 4 , DU-145 cells were slightly inhibited (19%) by electroporation with as750/15 compared with mock-treated controls; however, growth inhibition was not statistically significant (P Ͼ .05). Moreover, the anti-androgen bicalutamide (1 M) also resulted in a slight but insignificant inhibition of DU-145 cells (14% compared with mock-treated controls). Corresponding control ODNs (mm750/15 and ms750/15) did not inhibit DU-145 cell proliferation.
Reduced androgen-mediated growth stimulation and PSA secretion LNCaP cell growth and PSA production are stimulated by androgens. 25 To investigate the effects of AR downregulation on androgen-mediated cell proliferation and PSA secretion, cells were electroporated with or without ODNs (ms750/15, mm750/15, as750/15). After 24 hours, medium was changed into RPMI 1640 with 10% charcoal-stripped FCS, supplemented with increasing concentrations of the synthetic androgen mibolerone (1 pM to 2 nM). Cells were incubated for another 72 hours. Thereafter, cell mass was determined by MTT assay and PSA levels were measured by MEIA in cell culture supernatants. After a 72-hour incubation without mibolerone, there was already a significant difference in cell mass between controls and antisense-treated cells (P Ͻ .001) (Fig 5A) . With increasing concentrations of mibolerone, both controls and as750/15-treated cells showed the biphasic growth curve that is typical for LNCaP cells, with maximal stimulation at androgen concentrations of 0.1-2 nM. However, at all androgen concentrations, cell masses of antisense-treated samples were significantly lower compared with mock-treated controls (P Ͻ .05). Maximal androgen stimulation of antisense-treated cells for 72 hours with 1 nM mibolerone increased cell mass by 63% (P ϭ .02), whereas the increase was 80% in stimulated control oligonucleotide-treated cells. Furthermore, maximal stimulation at 1 nM mibolerone was significantly lower in antisense-treated cells (63% increased cell mass; P ϭ .02) compared with mock-treated controls (80% increased cell mass).
LNCaP cells secrete PSA after activation of the PSA gene by androgens. PSA levels in supernatants of mockelectroporated control cells reached a maximum of 29.14 Ϯ 4.71 ng/UA with a 72-hour incubation with 2 nM mibolerone (Fig 5B) . As750/15-treated cells produced significantly less PSA (13.17 Ϯ 3.21 ng/UA; P ϭ .006). PSA secretion in cells treated with mismatched or mis-sense control ODNs was not different from control LNCaP cells.
Similar results were obtained when PSA secretion was stimulated by IGF-I, a ligand-independent activator of the AR. 22, 31 In control cells (mock electroporation, mm750/15) 50 ng/mL IGF-I treatment for 72 hours significantly increased PSA levels by 3.8-and 3.0-fold, respectively (P ϭ .02). In contrast, PSA secretion was not increased in as750/15-treated cells (1.1-fold induction).
Treatment with antisense AR ODNs induces apoptosis in LNCaP cells
Does antisense down-regulation of AR expression inhibit LNCaP cells solely by inhibition of proliferation, or does it also have an effect on the rate of apoptosis? To answer this question, LNCaP cells were treated with control and antisense ODNs or cultured in the presence or absence of FCS. Apoptosis was determined after 48 hours by measurement of annexin V binding (Fig 6) . Under standard culture conditions (RPMI 1640 plus 10% FCS), a spontaneous apoptosis rate of ϳ4% was observed. Electroporation (mock treatment) increased the percentage of apoptotic cells under normal culture conditions to ϳ6%. Treatment with the antisense AR 
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ODN as750/15 (7.5 M) was associated with induction of apoptosis to 26% of the cells 48 hours after electroporation. The mismatched control ODN (mm750/15) also increased the rate of apoptosis (21%), but this increase was less than that seen for the antisense ODN.
Serum deprivation (RPMI 1640, 1% FCS) increased apoptosis in mock-electroporated LNCaP cells to ϳ12%, whereas the addition of mibolerone (5 nM) significantly reduced the number of apoptotic cells to ϳ3%. Mibolerone (5 nM) failed to overcome the effect 
Reduced EGFR expression after treatment with antisense AR ODNs
There is evidence that androgens up-regulate EGFR expression in prostate cancer cells. 26, 32 Therefore, we were interested in determining whether AR antisense treatment of LNCaP cells has any effects on the expression of EGFR. For this purpose, LNCaP cells were electroporated and grown in serum-reduced medium (RPMI 1640, 1% FCS) in the absence (control medium) or presence of 20 ng/mL EGF. EGFR levels were measured 48 hours afterward (Fig 7) . Treatment of cells with as750/15 caused a significant decrease in EGFR levels to about two-thirds of that seen for mock-electroporated controls (P ϭ .021). Stimulation with EGF (20 ng/mL) also lowered EGFR levels significantly in all cultures (P ϭ .020). Again, the lowest levels were measured in the AR antisense-treated cells. In these cultures, EGFR levels reached only half of the levels of mock-electroporated and control ODN-electroporated cells.
AR antisense-mediated growth inhibition of long-term androgen-ablated LNCaP-abl cells Recently, we reported on the establishment of a new LNCaP subline, LNCaP-abl, that was cultured over 10 months in androgen-depleted medium. LNCaP-abl cells display ϳ4-fold higher AR protein levels than normal controls, a hypersensitive response to androgenic stimulation, and a 30-fold higher basal AR transcriptional activity than LNCaP cells. In contrast to parental LNCaP cells, LNCaP-abl cells also grow in castrated nude mice. 14 We tested the efficacy of AR antisense treatment in LNCaP-abl cells, as these cells are a model for prostate cancer after long-term androgen ablation.
LNCaP-abl cells were electroporated with AR antisense (as750/15), with AR missense (ms750/15), or with mismatched control ODNs (mm750/15); results were compared with mock-treated controls. Immunoblot analysis revealed that AR protein levels could be effectively reduced by antisense treatment (Fig 8) . This down-regulation of AR protein was associated with significant growth inhibition (P ϭ .003) (Fig 9) . Mismatched and mis-sense control ODNs (mm750/15, ms750/15), respectively, again had no effect on AR protein expression or on cell growth of LNCaP-abl.
DISCUSSION
In the present study, we have investigated the efficiency of AR antisense treatment for inhibition of prostate cancer cells. We demonstrate that the specific downregulation of AR with antisense ODNs results in prostate tumor cell growth inhibition, reduced androgenmediated growth stimulation and PSA secretion, increased apoptosis, and decreased EGFR expression. We tested several ODNs directed against the N-terminal CAG and the GGC repeat regions and the translation start region of the human AR mRNA and found as750/ 15, a 15-base phosphorothioate ODN targeting the CAG repeat region, to be the most potent and AR-specific antisense ODN. To our knowledge, this is the first report on inhibition of human AR expression by antisense AR ODNs in cells expressing a functional human AR in vitro. The ODNs used in our study were only active when delivered by electroporation. Although several studies have reported satisfying antisense effects by simple incubation of cells with ODN-supplemented medium, other investigators postulated that permeabilization techniques such as the use of cationic liposomes [33] [34] [35] or electroporation 36, 37 are absolutely necessary for ODN uptake. This process is obviously dependent upon the structure, type, length, and sequence of the ODNs, as well as on cell type and culture conditions, 38 and might explain the variability of experimental designs.
ODNs directed against the start of the translation site of the AR were ineffective, whereas ODNs targeted to the N-terminal CAG and GGC repeat regions of the AR, respectively, exerted a strong antisense effect. We assume that ODNs that are directed against a triplet repeat sequence have a greater chance of binding to their respective target RNA, and are therefore more effective. Down-regulation of AR protein with antisense AR ODNs persisted for at least 72 hours in our experiments, although AR levels increased slowly after a minimum at 24 hours. The gradual abatement of the antisense effect may be explained by inactivation of ODNs by enzymatic degradation or by the release of ODNs by exocytosis. 39 Proliferation of antisense-treated LNCaP cells was completely inhibited compared with mock-treated controls after a 24-to 48-hour lag-phase.
Because AR protein was maximally reduced already after 24 hours and growth arrest occurred between 24 and 48 hours after antisense treatment, effects of AR down-regulation seem to be delayed in comparison with gene expression. As expected, androgen-induced PSA secretion as well as growth stimulation were distinctly reduced compared with mock-electroporated controls. Although antisense-treated cells also showed the typical biphasic growth pattern, similar to untreated LNCaP cells, in response to stimulation with androgen, the number of these cells was significantly lower at all androgen concentrations tested compared with the mock control. Similar results were obtained after incubation of cells with IGF-I. As shown in recent studies, IGF-I is a ligand-independent activator of the AR, resulting in stimulation of PSA secretion even in the absence of androgens. 22, 31 As expected, down-regulation of the AR in LNCaP cells also inhibited IGF-I-mediated PSA secretion.
Additional control experiments were performed with DU-145 cells that lack AR expression and grow independently of androgen in vitro. 40, 41 Mis-sense and mismatched control ODNs (ms750/15, mm750/15) did not inhibit DU-145 cell proliferation. In contrast, the as750/15 antisense ODN led to a slight inhibition of DU-145 cells; however, this effect was not statistically significant.
Blockade of androgen stimulation by hormonal castration is thought to lead to apoptosis of prostate epithelial cells that mostly results in a reduction of tumor volume. Serum starvation was associated with a moderate induction of apoptosis in LNCaP cells, whereas the addition of androgen prevented cells from programmed cell death. This is consistent with observations made by Raffo et al. 42 Antisense AR treatment also induced apoptosis. This effect was more pronounced than that observed with serum deprivation and could not be abrogated by mibolerone. Our observation that AR down-regulation is associated with induction of apoptosis supports data from Gao et al, 43 who reported that retinoic acid-induced apoptosis leads to a reduction of AR protein levels.
Another promising result was the observation that the long-term androgen-ablated LNCaP subline, LNCaPabl, which was recently established in our lab, 14 was significantly growth inhibited by antisense AR treatment. Although these cells express increased levels of AR, are hypersensitive to androgen, and have a higher AR transactivation activity, they respond to antisense AR treatment with significant growth retardation in comparison with mock-treated controls.
Although the effects of our AR antisense ODNs are promising, one could argue that growth inhibition might result from unspecific side effects rather than from AR down-regulation. It has been shown recently that degradation products of ODNs, nucleosides and nucleotides, can affect cell proliferation and differentiation (reviewed in Ref. 35) . To demonstrate that the ODNs do in fact exert specific AR antisense effects, we used different control ODNs, including mis-sense ODNs with random sequences as well as mismatched ODNs in which 4 of 15 nucleotides from the original antisense sequence were exchanged. These control ODNs did not have a significant effect on AR expression or on cell proliferation. However, one cannot rule out that in addition to the specific antisense effect, other mechanisms, such as direct toxicity or cleavage of nontargeted mRNA, may contribute to the inhibitory effects seen with the antisense oligonucleotide. Such side effects would explain the increase in apoptotic cells seen after treatment with the mismatched control ODN mm750/15. Electroporation is a harsh method of DNA delivery into cells and also increases apoptosis when applied alone. Therefore, the increased levels of apoptotic cells in the mismatched control group may result from a toxic effect of the ODN in combination with electroporation. This might lead to a state of early apoptosis that is detected by annexin V binding.
Comparative studies with the nonsteroidal anti-androgen bicalutamide, a "pure" anti-androgen that inhibits androgen-induced gene expression and cell growth, 44 revealed that the AR antisense ODN as750/15 is more effective in tumor cell growth inhibition than this commonly used nonsteroidal anti-androgen. These findings further demonstrate that down-regulation of AR expression by AR antisense ODNs might be more effective in tumor growth inhibition than AR inactivation by antiandrogen treatment. Anti-androgens such as bicalutamide and flutamide have been developed to overcome the problems of androgen withdrawal therapies that result only in a partial androgen deprivation. Nonsteroidal anti-androgens were intended to block androgen action by inhibiting AR function as a transcription factor, thus preventing androgens from the adrenal glands from stimulating prostate tumor growth. However, studies in the last few years have shown that in some patients, nonsteroidal anti-androgens act as agonists, especially in the context of mutated ARs. 15 Flutamide and nilutamide, for example, activate the AR of LNCaP cells, 17, 18 which contains a point mutation in the ligand-binding domain. 17 In contrast, bicalutamide was shown to retain its antagonistic effects in LNCaP cells. 45 In recent years, prostate cancer cell growth has been associated with various growth factors playing a major role in the shift from androgen dependence to androgen independence. In addition, androgen-mediated cell growth seems to be influenced, at least in part, by growth factors and their respective receptors. 46 The EGF and its corresponding receptor (EGFR) in particular have been studied intensively in terms of their modulation by androgens. Several studies have shown that administration of androgens results in EGFR up-regulation. 32, 47, 48 In concordance with these findings, AR antisense treatment resulted in a decrease of EGFR. EGF treatment also yielded a significant decrease in EGFR levels. In addition, we observed that treatment with both EGF and the antisense ODN as750/15 leads to a reduction in EGFR levels that is even higher than those reached with each compound alone. In summary, our results show that down-regulation of the AR leads to reduced EGFR levels. This is in contrast to the current situation in breast cancer, where EGFR expression is inversely correlated with expression of the estrogen receptor. 49 Estrogen receptor-negative breast tumors that express high levels of EGFR also tend to have a higher risk for progression; therefore, determination of EGFR expression is even used as a prognostic marker. 50, 51 Our findings suggest that, with respect to EGFR regulation by steroid receptors, mammary and prostate tumors are different.
The present study points out the possibility that prostate tumor cell growth can be inhibited by the application of antisense AR ODNs. Nevertheless, one has to keep in mind that the use of oligonucleotides might also have effects that cannot be evaluated by in vitro experiments, even by the use of different control ODNs. Therefore, in vivo studies are planned to explore the utility of this antisense technology for treatment of non-organ confined metastatic prostate cancer. It is also conceivable that antisense AR ODNs could be combined with any of the currently available forms of androgen ablation therapy to affect all of the heterogenous tumor cell populations present within an individual patient with prostate cancer. As AR down-regulation also induces a pronounced reduction of EGFR levels, one can suppose that AR down-regulation also influences the expression of many other genes either directly or indirectly. In this respect, the application of antisense ODNs to down-regulate AR expression raises the exciting possibility of gaining a better understanding about the role of the AR in gene regulation and critical molecular events responsible for prostatic disease.
